Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | preprocathepsin c precursor, putative | 0.0156 | 0.4995 | 1 |
Toxoplasma gondii | cathepsin CPC1 | 0.0156 | 0.4995 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 1 | 0.0156 | 0.4995 | 1 |
Echinococcus granulosus | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Echinococcus granulosus | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Schistosoma mansoni | SmCB2 peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Giardia lamblia | Dipeptidyl-peptidase I precursor | 0.0156 | 0.4995 | 0.4995 |
Plasmodium vivax | dipeptidyl aminopeptidase 2, putative | 0.0156 | 0.4995 | 1 |
Plasmodium falciparum | dipeptidyl aminopeptidase 2 | 0.0156 | 0.4995 | 1 |
Trypanosoma cruzi | cysteine peptidase C (CPC), putative | 0.0163 | 0.5383 | 0.5 |
Plasmodium vivax | dipeptidyl aminopeptidase 1, putative | 0.0156 | 0.4995 | 1 |
Echinococcus multilocularis | cathepsin b | 0.0163 | 0.5383 | 0.5 |
Schistosoma mansoni | cathepsin B-like peptidase (C01 family) | 0.0163 | 0.5383 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 73 uM | Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation | ChEMBL. | 26001344 |
MCC (ADMET) | > 100 uM | Cytotoxicity against HEL cells assessed as alternation of cell morphology by microscopic analysis | ChEMBL. | 26001344 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.